Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma.

Kit I TongSharon YoonKeren IsaevMehran BakhtiariTracy LackrajMichael Y HeJesse JoyntAnjali SilvaMaria C XuGilbert G PrivéHousheng Hansen HeRodger E TiedemannElizabeth A ChavezLauren C ChongMerrill BoyleDavid W ScottChristian SteidlRobert Kridel

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Our data underscore the synergistic interplay between IKAROS degradation and EZH2 inhibition on modulating epigenetic changes and ultimately enhancing antitumor effects in DLBCL.

Keyphrases

diffuse large b cell lymphoma
epstein barr virus
long non coding rna
long noncoding rna
dna methylation
gene expression
electronic health record
signaling pathway
cancer therapy
machine learning
data analysis
drug delivery